GRI Bio (GRI) Other Non-Current Assets (2020 - 2022)
GRI Bio (GRI) posted quarterly Other Non-Current Assets of $169000.0 for Q2 2022, down 30.45% year-over-year from $243000.0 in Q2 2021, and down 9.63% quarter-over-quarter from $187000.0 in Q1 2022.
GRI Bio (GRI) Other Non-Current Assets (2020 - 2022) Analysis & Trends
GRI Bio's Other Non-Current Assets history runs 3 years deep, the most recent figure standing at $169000.0 for Q2 2022.
- In Q2 2022, Other Non-Current Assets fell 30.45% year-over-year to $169000.0; the TTM figure through Jun 2022 stood at $169000.0 (down 30.45% YoY), while the FY2021 annual figure was $206000.0, down 26.16% from the prior year.
- Other Non-Current Assets for Q2 2022 stood at $169000.0, down from $187000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $279000.0 in Q4 2020, with the low at $169000.0 in Q2 2022.
- The 3-year median for Other Non-Current Assets is $215000.0 (2021), against an average of $218000.0.
- The sharpest annual moves came in 2021 and 2022: Other Non-Current Assets retreated 26.16% in 2021, then slumped 30.45% in 2022.
- GRI Bio's Other Non-Current Assets stood at $279000.0 in 2020, then declined by 26.16% to $206000.0 in 2021, then retreated by 17.96% to $169000.0 in 2022.
- Business Quant data shows GRI's Other Non-Current Assets at $169000.0 in Q2 2022, $187000.0 in Q1 2022, and $206000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 169,000.00 |
| Mar 31, 2022 | 187,000.00 |
| Dec 31, 2021 | 206,000.00 |
| Sep 30, 2021 | 224,000.00 |
| Jun 30, 2021 | 243,000.00 |
| Dec 31, 2020 | 279,000.00 |